Study: CSII treatment boosts glucose control in type 1 diabetes

Continuous subcutaneous insulin infusion treatment was effective in lowering HbA1C levels in children with type 1 diabetes, with improvements sustained at 48 months, according to a study presented at the annual meeting of the Pediatric Academic Societies. CSII treatment lacks cost-effectiveness but is safe and well-tolerated compared with multiple daily injections, researchers said.

View Full Article in:

CSII therapy improved HbA1c in children with type 1 diabetes - Endocrine Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN